Viewing nowCombinationPromet Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceutical Co., Ltd.

MFDS item code 202204597 · Approved 2022.12.21 · Insurance code 654006000
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps improve blood glucose control in patients with type 2 diabetes when used in conjunction with diet and exercise. The combined action of sitagliptin and metformin effectively regulates blood glucose. This helps maintain stable blood glucose levels in patients. Therefore, this medication plays an important role in the management of blood glucose in patients with type 2 diabetes.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains both sitagliptin and metformin and is used for diabetes treatment. When taking this medication, care should be taken to avoid allergic reactions. Rarely, severe allergic reactions or skin disorders may occur, so if such symptoms appear, immediately stop taking the medication and consult a physician. Additionally, a serious inflammation of the pancreas known as pancreatitis may occur, so if symptoms such as abdominal pain, nausea, or vomiting arise, seek medical attention immediately. The metformin component can cause a rare but fatal metabolic abnormality called lactic acidosis, so it is safe for patients with impaired kidney function or liver problems not to use this medication. This medication should not be administered to patients with moderate to severe renal impairment, acute heart problems, severe infections, or dehydration. Treatment should be temporarily discontinued before and after examinations using iodinated contrast agents, and it should only be resumed after confirming normal kidney function. This medication is not recommended for use in pregnant women or nursing mothers. This medication may increase the risk of hypoglycemia or lactic acidosis in cases of irregular meals, intense exercise, or concurrent use with other medications, so caution is required. During treatment, regular monitoring of kidney function and blood tests should be performed, and it is advisable to check vitamin B12 levels as well. Alcohol consumption may increase the risk of side effects from this medication, so it is advisable to avoid it during treatment. Hypoglycemic symptoms may occur, especially when used in conjunction with insulin or sulfonylureas, so blood glucose changes should be monitored closely. If bullous skin disorders or severe joint pain occur during the use of this medication, it is important to inform a doctor immediately, and the medication may be discontinued if necessary. In the event of overdose, seek immediate medical attention for appropriate treatment, and blood dialysis may be beneficial. Finally, this medication is not recommended for use in children under 18 years of age, as its safety and effectiveness have not been adequately established.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air or moisture ingress, and it is advisable to keep it at room temperature between 1°C and 30°C. Proper storage will help maintain the medication's efficacy.
Bright pink oval film-coated tablet
56 tablets/box[(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.